The use of TNF-α blocking agents in rheumatoid arthritis: An overview

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 3, 2004, Pages 581-594

  Toussirot, Éric ^a   Wendling, Daniel ^a  

^a UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

Author keywords

Biological therapies; Cytokines; Rheumatoid arthritis; TNF

Indexed keywords

ADALIMUMAB; AMYLOID A PROTEIN; AZATHIOPRINE; C REACTIVE PROTEIN; CERTOLIZUMAB PEGOL; CORTICOSTEROID; CYCLOSPORIN; CYTOKINE; DOUBLE STRANDED DNA; ETANERCEPT; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYBRID PROTEIN; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; LEFLUNOMIDE; LENERCEPT; METHOTREXATE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; UNINDEXED DRUG;

CELL CULTURE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CROHN DISEASE; DEMYELINATING DISEASE; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TARGETING; GENE OVEREXPRESSION; HEADACHE; HISTOPLASMOSIS; HUMAN; IN VITRO STUDY; INFLUENZA; INJECTION SITE; LISTERIOSIS; LUNG ASPERGILLOSIS; LYMPHOMA; NAUSEA; NONHUMAN; PATHOGENESIS; PNEUMOCYSTIS PNEUMONIA; PRACTICE GUIDELINE; PROTEIN STRUCTURE; REVIEW; RHEUMATOID ARTHRITIS; SKIN MANIFESTATION; STRUCTURE ANALYSIS; SYNOVIOCYTE; SYNOVIUM; TUBERCULOSIS;

EID: 1542610001     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.3.581     Document Type: Review

References (83)

1. HARRIS E. Clinical features of rheumatoid arthritis. In: Textbook of rheumatology. Kelley W, Harris E, Ruddy S, Sledge C (Eds), WB Saunders & Co, Philadelphia, USA (1993):874-911.
2. HARRIS E. Etiology and pathogenesis of rheumatoid arhtritis. In: Textbook of rheumatology. Kelley W, Harris E, Ruddy S, Sledge C (Eds), WB Saunders & Co, Philadelphia, USA (1993):833-873.
3. CHOY HS, PANAYI GS: Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med. (2001) 344:907-916.
4. FELDMANN M, BRENNAN FM, MAINI RN: Role of cytokines in rheumatoid arthritis. Ann. Rev. Immunol. (1996) 14:397-440.
5. AREND WP, DAYER JM: Inhibition of the production and effects of interleukin-1 and tumor necrosis factor-α in rheumatoid athritis. Arthritis Rheum. (1995) 38:151-160.
6. MAINI RN, ELLIOTT MJ, BRENNAN F et al.: Monoclonal anti-TNF-α antibody as a probe of pathogenesis and therapy of rheumatoid arthritis. Immunol. Rev. (1995) 144:195-223.
7. FELDMANN M, BONDESON J, BRENNAN F et al.: The rationale for the current boom in anti-TNF-α treatment. Is there an effective means to define therapeutic targets for drugs that provide all the benefits of anti-TNF-α and minimize hazards? Ann. Rheum Dis. (1999 58(Suppl. I):i27-i31.
8. KOLLIAS G, DOUNI E, KASSIOTIS G et al.: On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Immunol. Rev. (1999) 169:175-194.
9. FELDMANN M, MAINI RN: Discovery of TNF-α as atherapeutic target in rheumatoid arthritis. Preclinical and clinical studies. Joint Bone Spine (2002) 69:12-18.
10. FLIER JS, UNDERHILL LH: The tumor necrosis factor ligand and receptor families. N. Engl. J. Med. (1996) 334:1717-1725.
11. DINARELLO CA, MOLDAWER LL:THe tumor necrosis factor (TNF) superfamily and its receptor. In: Proinflammatory and anti-inflammatory cytokines in rheumatoid arthritis. Dinarello CA & Moldaver LL (Eds), Amgen, Thousand Oaks, USA (2000):77-97.
12. IDRISS H, NAISMITH JH: TNF-α and the TNF receptor superfamily: Structure-function relationship(s). Microsc. Res. Tech. (2000) 50:184-195.
13. KALDEN JR. Expanding role of biologic agents in rheumatoid arthritis. J. Rheumatol. (2002) 29(Suppl. 66):27-37.
14. PALEOLOG E: The therapeutic potential of TNF-α blockade in rheumatoid arthritis. Expert Opin. Investig. Drugs (2003) 12:1087-1095.
15. MAINI RN, TAYLOR PC, PALEOLOG E et al.: Anti-tumour necrosis factor specific antibody (infliximab) treatment provides insights into the pathophysiology of rheumatoid arhritis. Ann. Rheum. Dis. (1999) 58(Suppl. I):i56-i60.
16. HARRIMAN G, HARPER LK, SCHAIBLE TF: Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNF-α treatment. Ann. Rheum. Dis. (1999) 58(Suppl. I):i61-i64.
17. MARKHAM A, LAMB HM: Infliximab. A review of its use in the management of rheumatoid arthritis. Drugs (2000) 59:1341-1359.
18. ELLIOTT MJ, MAINI RN, FELDMANN M et al.: Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor-α. Arthritis Rheum. (1993) 36:1681-1690.
19. ELLIOTT MJ, MAINI RN, FELDMANN M et al.: Randomized double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet (1994) 344:1105-1110.
20. MAINI RN, BREEDVELD FC, KALDEN JR et al.: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor-α monoclonal antibody combined with low dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. (1998) 41:1552-1563.
21. KAVANAUGH A, STCLAIR EW, MCCUNE WJ et al.: Chimeric anti-tumor necrosis factor-α monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J. Rheumatol. (2000) 27:841-850.
22. MAINI RN, STCLAIR EW, BREEDVELD FC et al., for the ATTRACT study group: Infliximab (chimeric anti-tumour necrosis factor-α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomittant methotrexate: A randomised Phase III trial. Lancet (1999) 354:1932-1939.
23. LIPSKY P, VAN DER HEIJDE DMFM, STCLAIR EW et al. for the ATTRACT study group: Infliximab and methotrexate in the treatment of rheumatoid arthritis. N. Engl. J. Med. (2000) 343:1594-1602.
24. PAULUS H, EGGER M, WARD J et al.: Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying and-rheumatic drugs, based on findings in patients treated with placebo. Arthritis Rheum. (1990) 33:477-484.
25. FELSON D, ANDERSON J, BOERS M et al.: American College of Rheumatology preliminary definitions of improvement in rheumatoid arthritis. Arthritis Rheum. (1995) 38:727-735.
26. ETANERCEPT: Soluble tumour necrosis factor receptor, TNF receptor fusion protein, TNFR-Fc, TNR 001, Enbrel. Drugs R&D (1999) 1:258-261.
27. GARRISTN L, MCDONNEL ND: Etanercept: therapeutic use in patients with rheumatoid arthritis. Ann. Rheum. Dis. (1999) 58(Suppl. I):i65-i69.
28. SPENCER-GREEN GU Etanercept (Enbrel): update on therapeutic use. Ann. Rheum. Dis. (2000) 59(Suppl. I): I46-i49.
29. MORELAND LW, BAUMGARTNER SW, SCHIFF MH et al.: Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N. Engl. J. Med. (1997) 337:141-147.
30. MORELAND LW, SCHIFF MH, BAUMGARTNER SW et al.: Etanercept therapy in rheumatoid arthritis. Ann. Intern. Med. (1999) 130:478-86.
31. WEINBLATT ME, KREMER JM, BANKHURST AD et al.: A trial of etanercept, a recombinant tumor necrosis factor receptor Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N. Engl. J. Med. (1999) 340:253-259.
32. BATHON JM, MARTIN RW, FLEISCHMANN RM et al.: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N. Engl. J. Med. (2000) 343:1586-1593.
33. GENOVESE MC, BATHON JM, MARTIN RW et al.: Etanercept versus methotrexate in patients with early rheumatoid arthritis. Two-year radiographic and clinical outcomes. Arthritis Rheum. (2002) 46:1443-1450.
34. MACHOLD KP, SMOLEN JS: Adalimumab - a new TNF-α antibody for treament of inflammatory joint disease. Expert Opin. Biol. Ther. (2003) 3:351-360.
35. KEMPENI J: Preliminary results of early clinical trials with the fully human anti-TNF-α monoclonal antibody D2E7. Ann. Rheum. Dis. (1999) 58(Suppl. I):i70-i72.
36. KEMPENI J:AUpdate on D2E7: a fully human anti-tumour necrosis factor-α monoclonal antibody. Ann. Rheum. Dis. (2000) 59(Suppl. I):i44-i45.
37. DEN BROEDER A, VAN DE PUTTE LBA, RAU R et al.: A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-α antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J. Rheumatol. (2002) 29:2288-2298.
38. VAN GESTEL A, PREVOO M, VANT HOF M et al.: Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Arthritis Rheum. (1995) 39:34-40.
39. DEN BROEDER AA, JOOSTEN LAB, SAXNE T et al.: Long term anti-tumour necrosis factor α monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation. Ann. Rheum. Dis. (2002) 61:311-318.
40. BARRERA P, VAN DER MAAS A, VAN EDE AE et al.: Drug survival, efficacy and toxicity of monotherapy with a fully human anti-tumour necrosis factor-α antibody compared with methotexate in long standing rheumatoid arthritis. Rheumatology (2002) 41:430-439.
41. WEINBLATT ME, KEYSTONE EC, FURST DE et al.: Adalimumab, a fully human anti-tumor necrosis factor-α monoclonal antibody for the treatment of rheumatoid arthritis in patients taking concomittant methotrexate. The ARMADA trial. Arthritis Rheum. (2003) 48:35-45.
42. RAU R, HERBORN G, SANDER O et al.: Long-term treatment with the fully human anti-TNF antibody D2E7 slows radiographic disease progression in rheumatoid arthritis. Athritis Rheum. (1999) 42(Suppl.):S400 (Abstract).
43. KEYSTONE E, KAVANAUGH AF, SHARP J et al.: Adalimumab (D2E7), a fully human anti-TNF-α monoclonal antibody inhibits the progression of structural joint damage in patients with active RA despite concomitant methotrexate therapy (Abstract). Arthritis Rheum. (2003) 48(Suppl.):S205.
44. ROSE-JOHN S, SCHOOLTINK H: CDP-870. Curr. Opin. Invest. Drugs (2003) 4:588-592.
45. CHOY EHS, HAZLEMAN B, SMITH M et al.: Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: A Phase II double-blinded, randomized, dose-escalating trial. Rheumatology (2002) 41:1133-1137.
46. DARLINGTON C: PEG-sTNF-RI. Curr. Opin. Invest. Drugs (2003) 4:583-587.
47. EDWARDS CK: PEGylated recombinant human soluble tumour necrosis factor receptor Type I (r-Hu-sTNF-RI): Novel high affinity TNF receptor designed for chronic inflammatory diseases. Ann. Rheum. Dis. (1999) 58(Suppl. I):i73-i81.
48. DAVIS M, FEIGE U, BENDELE AM et al.: Treatment of rheumatoid arthritis with PEGylated recombinant human soluble tumour necrosis factor receptor Type I: A clinical update. Ann. Rheum. Dis. (2000) 59(Suppl. I):i43-i43.
49. MORELAND LW, MCCABE DP, CALDWELL JR et al.: Phase I/II trial of recombinant methionyl human tumor necrosis factor binding protein PEGylated dimer in patients with active refractory rheumatoid arthritis. J. Rheumatol. (2000) 27:601-609.
50. CDP571: Anti-TNF monoclonal antibody, BAY 103356, BAY W 3356, Humicade. Drugs R&D (2003) 4:174-178.
51. RANKIN ECC, CHOY EHS, KASSIMOS D et al.: The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br. J. Rheumatol. (1995) 34:334-342.
52. CHOY EHS, RANKIN ECC, KASSIMOV D et al.: The engineered human anti-tumor necrosis factor-α antibody CDP571 inhibits inflammatory pathways but not T cell activation in patients with rheumatoid arthritis. J. Rheumatol. (1999) 26:2310-2317.
53. RAU R, SANDER O, VAN RIEL P et al.: Intravenous human recombinant tumor necrosis factor receptor p55 IgG1 fusion protein Ro 45-2081 (lenercept): A double blind, placebo controlled dose-finding study in rheumatoid arthritis. J. Rheumatol. (2003) 30:680-690.
54. FURST DE, WEISMAN M, PAULUS HE et al.: Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein, Ro 45-2081 (lenercept): Results of a dose-finding study in rheumatoid arthritis. J. Rheumatol. (2003) 30:2123-2126.
55. MORELAND LW, COHEN SB, BAUMGARTNER SW et al.: Long term safety of etanercept in patients with rheumatoid arthritis. J. Rheumatol. (2001) 28:1238-1244.
56. WEISMAN MH: What are the risks of biologic therapy in rheumatoid arthritis? An update on safety. J. Rheumatol. (2002) 29(Suppl. 65):33-68.
57. MARIETTE X: Inhibiteurs dE TNF-α en 2002: effets indésirables, surveillance, nouvelles indications en dehors de la polyarthrite rhumatoïde et des spondylarthropathies. Rev. Rhum. (2002) 69:982-991.
58. KEANE J, GERSHON S, WISE RP et al.: Tuberculosis associated with infliximab, a tumor necrosis factor-α-neutralizing agent. N. Engl. J. Med. (2001) 345:1098-1104.
59. ROTH S, DELMONT E, HEDIER P et al.: Anticorps anti-TNF-α (infliximab) et tuberculose: à propos de trois cas. Rev. Med. Interne (2002) 23:312-316.
60. MAYORDOMO L, MARENCO JL, GOMEZ-MATEOS J et al.: Pulmonary miliary tuberculosis in a patient with anti-TNF-alpha treatment. Scand. J. Rheumatol. (2002) 31:44-45.
61. ELLERIN T, RUBIN RH, WEINBLATT: Infections and anti-tumor necrosis factor α therapy. Arthritis Rheum. (2003) 48(11 ):3013-3022.
62. MOHAN VP, SCANGA CA, YU K et al.: Effects of tumor necrosis factor alpha on the immune response in chronic persistent tuberculosis: A possible role for limiting pathology. Infect. Immun. (2001) 69:1847-1855.
63. GOMEZ-REINO JJ, CARMONA L, VALVERDE VR et al.: Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk. A multicenter active-surveillance report. Arthritis Rheum. (2003) 48:2122-2127.
64. FURST DE, CUSH J, KAUFMAN S et al.: Preliminary guidelines for diagnosing and treating tuberculosis in patients with rheumatoid arthritis in immunosuppressive trials or being treated with biological agents. Ann. Rheum. Dis. (2002) 6(Suppl. II):iI62-ii63.
65. ABITBOL V, BERENBAUM F, BREBAN M et al.: Recommendations about the prevention and management of tuberculosis in patients taking infliximab. Joint Bone Spine (2002) 69:170-172.
66. KROESEN S, WIDMER AF, TYNDALL A et al.: Serious bacterial infections in patients with rheumatoid arthritis under anti TNF-α therapy. Rheumatology (2003) 42:617-621.
67. LEE JH, SLIFMAN NR, GERSHON SK et al.: Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor-α antagonists infliximab and etanercept. Arthritis Rheum. (2002) 46:2565-2570.
68. SLIFMAN NR, GERSHON SK, LEE JH et al. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor α-neutralizing agents. Arthritis Rheum. (2003) 48:319-324.
69. MOHAN N, EDWARDS ET, CUPPS TR et al.: Demyelination occuring during anti-tumor necrosis factor-α therapy for inflammatory arthritides. Arthritis Rheum. (2001) 44:2862-2869.
70. ROBINSON WH, GENOVESE MC, MORELAND LW: Demyelinating and neurologic events reported in association with tumor necrosis factor-α antagonism. By what mechanisms could tumor necrosis factor-α antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis. Arthritis Rheum. (2001) 44:1977-1983.
71. BROWN SL, GREENE MH, GERSHON SK et al.: Tumor necrosis factor antagonist therapy and lymphoma development. Twenty-six cases reported to the food and Drug Administration. Arthritis Rheum. (2002) 46:3151-3158.
72. MARIETTE X, CAZALS-HATEM D, WARSZAWKIL J et al.: Lymphomas in rheumatoid arthritis patients treated with methotrexate: A 3-year prospective study in France. Blood (2002) 99:3909-3915.
73. SHAKOOR N, MICHALSKA M, HARRIS CA et al.: Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet (2002) 359:579-80.
74. DE BANDT M, VITECOQ O, DESCAMPS V et al.: Anti-TNF-alpha induced systemic lupus syndrome. Clin. Rheumatol. (2003) 22:56-61.
75. CHARLES PJ, SMEENK RJ, DE JONG J et al.: Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: Findings in open-label and randomized placebo-controlled trials. Arthritis Rheum. (2000) 43:2383-2390.
76. DE RYCKE L, KRUITHOF E, VAN DAMME N et al.: Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum. (2003) 48:1015-1023.
77. SHERGY WJ, ISERN RA, COOLEY DA et al.: Open label study to assess infliximab safety and timing onset of clinical benefit among patients with rheumatoid arthritis. J. Rheumatol. (2002) 29:667-677.
78. KWON HJ, COTE TR, CUFFE MS et al.: Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann. Intern. Med. (2003) 138:807-811.
79. SMOLEN JS, BREEDVELD FC, BURMESTER GR et al.: Consensus statement on the initiation and continuation of tumor necrosis factor blocking therapies in rheumatoid artrhitis. Ann. Rheum. Dis. (2000) 59:504-505.
80. PREVOO MLL, VANTHOF MA, KUPER HH et al.: Modified disease activity scores that include twenty-eight joint counts. Arthritis Rheum. (1995) 38:44-48.
81. MUGNIER B, BALANDRAUD N, DARQUE A et al.: Polymorphism at position-308 of the tumor necrosis factor-α gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis Rheum. (2003) 48:1849-1852.
82. JOBANPUTRA P, BARTON P, BRYAN S et al.: The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: A systematic review and economic evaluation. Health Technol. Assess. (2002) 6:1-110.
83. KOBELT G, JÖNSSON L, YOUNG A et al.: The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and United-Kingdom based on the ATTRACT study. Rheumatology (2003) 42:326-335.